Provided by Tiger Trade Technology Pte. Ltd.

Ocular Therapeutix

9.87
-0.3200-3.14%
Pre-market: 9.900.0300+0.30%04:00 EDT
Volume:3.41M
Turnover:34.19M
Market Cap:2.16B
PE:-6.98
High:10.32
Open:10.21
Low:9.81
Close:10.19
52wk High:16.44
52wk Low:6.23
Shares:218.91M
Float Shares:185.00M
Volume Ratio:1.47
T/O Rate:1.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4140
EPS(LYR):-1.4203
ROE:-72.99%
ROA:-34.95%
PB:4.15
PE(LYR):-6.95

Loading ...

Ocular Therapeutix Price Target Maintained with a $25.00/Share by HC Wainwright & Co.

Dow Jones
·
Yesterday

Ocular Therapeutix: Buy Rating Reiterated on AXPAXLI Regulatory Progress and Durability Profile; Price Target Maintained at $25

TIPRANKS
·
Yesterday

Ocular Therapeutix Plans to File Eye Disease Drug Marketing Application in Q4

MT Newswires Live
·
Sep 15

Ocular Therapeutix completes pre-NDA meeting with FDA for Axpaxli

TIPRANKS
·
Sep 15

Ocular Therapeutix™ Announces Positive Pre-Nda Meeting with U.S. FDA for Axpaxli™ in Wet Amd

THOMSON REUTERS
·
Sep 15

Ocular - Accelerates Commercial Readiness for Potential 2027 Axpaxli Launch

THOMSON REUTERS
·
Sep 15

Ocular - to Submit Axpaxli Nda in Q4 2026

THOMSON REUTERS
·
Sep 15

Ocular Therapeutix™ Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI™ in Wet AMD

GlobeNewswire
·
Sep 15

Ocular Therapeutix (OCUL) Prepares New AXPAXLI Data, Is The Stock Still Below Fair Value?

Simply Wall St.
·
Sep 03

Ocular Therapeutix Joins Baird Global Healthcare Conference Fireside Chat

Reuters
·
Sep 01

Ocular Therapeutix™ to Participate in September and October Investor and Scientific Conferences

GlobeNewswire
·
Sep 01

Ocular Therapeutix (OCUL) Could Be 60% Below Fair Value As Axpaxli Story Builds

Simply Wall St.
·
Aug 25

Ocular Therapeutix Earns Buy Rating as Axpaxli Differentiation and LUGANO TKI Data Bolster Confidence in Lead Asset

TIPRANKS
·
Aug 17

Ocular Therapeutix rises 10.4%

TIPRANKS
·
Aug 17

Rival Ocular Therapeutix Shares up 8%

THOMSON REUTERS
·
Aug 17

Ocular Therapeutix Shares up 12.7% Premarket After Rival EyePoint's Eye Drug Misses Main Goal in Late-Stage Trial

THOMSON REUTERS
·
Aug 17

Ocular Therapeutix Grants New SVP Beth Rada Options for 85,000 Shares, 28,000 RSUs Under Inducement Plan

Reuters
·
Aug 14

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 14

Ocular Therapeutix Grants Inducement Awards to New Hires, Including Options Priced at $8.4 Per Share

Reuters
·
Aug 08

Ocular Therapeutix™ Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 08